Pricing Log in Create free account

Pasithea Therapeutics Corp. (KTTA) vs Lipocine Inc. (LPCN)

Pasithea Therapeutics Corp. and Lipocine Inc. are both Biotechnology companies. Pasithea Therapeutics Corp. and Lipocine Inc. are of similar size ($13.9M and $13.7M). Pasithea Therapeutics Corp. has the higher net margin (0.00% vs −755.1%) and the lower return on invested capital (−367.5% vs 0.00%). Across the 16 metrics below, Lipocine Inc. leads on 9 and Pasithea Therapeutics Corp. on 7.

Valuation

Metric KTTA LPCN Biotechnology median
P/E n/m n/m 8.50
P/S 27.71 7.75 9.71
P/B 0.27 0.56 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 1.39 0.64 0.64
EV/Sales (66.34) (5.21) 9.21
Earnings yield (376.19%) (126.35%) (33.15%)
Free cash flow yield (130.85%) (92.84%) (25.50%)

Profitability

Metric KTTA LPCN Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (800.80%) 0.00%
Net margin 0.00% (755.11%) 0.00%
Free cash flow margin 0.00% (713.02%) 0.00%
Return on equity (65.49%) (60.94%) (56.36%)
Return on assets (61.97%) (55.89%) (48.04%)
Return on invested capital (367.46%) 0.00% 0.00%

Growth

Metric KTTA LPCN Biotechnology median
Revenue growth (TTM) — (63.48%) 6.02%
EPS growth (last fiscal year) 77.07% (93,988.89%) 30.26%
Revenue growth, 5-year CAGR — 64.32% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KTTA LPCN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 26.25 11.48 4.72
Net debt to EBITDA 2.74 1.42 0.96

Dividend

Metric KTTA LPCN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric KTTA LPCN Biotechnology median
Market cap 13.70m 13.85m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack